In November I attended the Festival of Biologics (FoB) 2022 conference in Basel, Switzerland. Originally a set of different conferences (now called agendas) that has merged into a single conference, FoB focuses on anything related to biologics. One of the agendas is an antibody specific agenda, derived from the former European Antibody Congress. This year the antibodies agenda had more than 100 talks across multiple tracks, covering many different aspects of using antibodies as therapeutics, making it an exciting conference for an antibody enthusiast. However, while FoB does include talks on machine learning and bioinformatics, most are focused solely on experimental work. Another drawback is that the majority of the talks are by industry, with the few academic speakers almost all also representing a company. This meant that of the few talks about computational methods and tools for protein design, most felt more like a commercial rather than a research presentation. Nonetheless, FoB is still an interesting conference to attend when you are working on applied research for antibody therapeutics. It is an amazing opportunity to hear about which antibody specific problems companies are trying to overcome, which are deemed solved and which are the future problems to solve.